

**Supplement Table 1.** Survival rates of patients with rectal cancer according to different ypT and CRM status.

<i>pT</i>	Survival		<i>pT</i> with CRM	Survival	
	Total	N (%)		Total	N (%)
<i>pT0</i>	756	666 (88.10)	<i>pT0</i>		
			CRM(-)	755	665 (88.08)
			CRM(+)	1	1 (100.00)
<i>pT1</i>	204	187 (91.67)	<i>pT1</i>		
			CRM(-)	235	215 (91.49)
			CRM(+)	1	1 (100.00)
<i>pT2</i>	1,037	876 (84.47)	<i>pT2</i>		
			CRM(-)	1,035	875 (84.54)
			CRM(+)	2	1 (50.00)
<i>pT3</i>	2,118	1,521 (71.81)	<i>pT3</i>		
			CRM(-)	1,986	1,460 (73.51)
			CRM(+)	132	61 (46.21)
<i>pT4</i>	193	94 (48.70)	<i>pT4</i>		
			CRM(-)	121	64 (52.89)
			CRM(+)	72	30 (41.67)

**Supplement Figure 1.** The ROC between ypT and new category pT in rectal cancer patients treated with neoadjuvant chemoradiotherapy and surgery.

